INDICATIONS AND USAGE（适应症）

Adjuvant Treatment of Postmenopausal Women

AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy.

Advanced Breast Cancer in Postmenopausal Women

AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

DOSAGE（服用剂量）

The recommended dose of AROMASIN in early and advanced breast cancer is one 25 mg tablet once daily after a meal.

Adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy.

The treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

ADVERSE REACTIONS（不良反应）

Reductions in Bone Mineral Density (BMD)

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/cf066b7a-032a-416c-8d40-15ba581423e3/spl-doc?hl=exemestane

xtaneinformation